)
10X Genomics (TXG) investor relations material
10X Genomics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 revenue was $151M, with $1.6M from a Takara settlement; excluding non-recurring items, revenue was $149M, up 3% YoY.
Strong customer response and high order volume for the new Atera platform, with significant early adoption across academia and biopharma.
Robust growth in Chromium consumables and continued strength in spatial analysis, especially Xenium.
Acquisition of Proteintech Genomics to enhance proteomics and multiomics capabilities.
Strategic partnerships with Cleveland Clinic and Lausanne University Hospital to advance oncology diagnostics.
Financial highlights
Consumables revenue grew 7% YoY, with single-cell up 3% and spatial up 16%.
Instrument revenue declined 47% YoY, with Chromium down 46% and spatial instruments down 48%.
Gross margin increased to 74% from 72% YoY, aided by lower manufacturing costs and tariff refunds.
Operating expenses were $132.1M, nearly flat YoY when excluding litigation settlement gains.
Cash, equivalents, and marketable securities totaled $552M as of June 30, 2026.
Outlook and guidance
Full-year 2026 revenue guidance raised to $610M–$630M, representing 2–5% growth over 2025, excluding non-recurring items.
Expect to ship ~40 Atera instruments in 2026, with most shipments in Q4; booked orders already exceed this number.
Q3 revenue expected to see a modest sequential step down due to spatial product transition, with a significant Q4 step up as Atera ramps.
Guidance assumes no improvement in the macro environment or academic funding flows.
Operating expenses (excluding settlements) are expected to modestly decrease in 2026 due to ongoing cost management.
- Atera's launch drives strong demand and positions the company for future growth and innovation.TXG
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 9% adjusted, gross margin at 70%, and Atera launch drives strong demand.TXG
Q1 2026 - Q4 revenue beat guidance as consumables surged, but instrument sales lagged amid CapEx headwinds.TXG
Q4 2025 - Q3 2025 revenue hit $149M, with strong spatial growth and improved margins amid macro headwinds.TXG
Q3 2025 - Q2 revenue up 13% with $68M settlement; Scale Biosciences acquisition and funding headwinds noted.TXG
Q2 2025 - Q3 revenue fell 1% as spatial consumables soared and instruments lagged amid restructuring.TXG
Q3 2024 - Q2 revenue up 4% to $153.1M; guidance lowered amid macro headwinds and restructuring.TXG
Q2 2024 - Q1 2025 revenue $154.9M–$155M, core down 2%, guidance withdrawn amid funding uncertainty.TXG
Q1 2025 - 2024 revenue dipped 1% as new products launched; 2025 outlook is flat with NIH risks.TXG
Q4 2024
Next 10X Genomics earnings date
Next 10X Genomics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage